Mark E. Boulding's most recent trade in PTC Therapeutics Inc was a trade of 2,813 Common Stock done at an average price of $46.5 . Disclosure was reported to the exchange on July 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 06 Jul 2026 | 2,813 | 108,085 (0%) | 0% | 46.5 | 130,917 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2026 | 2,813 | 28,125 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 06 Jul 2026 | 2,266 | 107,538 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2026 | 2,226 | 4,532 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 84.41 per share. | 06 Jul 2026 | 1,036 | 106,662 (0%) | 0% | 84.4 | 87,449 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 84.41 per share. | 06 Jul 2026 | 833 | 106,392 (0%) | 0% | 84.4 | 70,314 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 86.38 per share. | 06 Jul 2026 | 745 | 105,272 (0%) | 0% | 86.4 | 64,353 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 85.84 per share. | 06 Jul 2026 | 645 | 106,017 (0%) | 0% | 85.8 | 55,367 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 86.38 per share. | 06 Jul 2026 | 601 | 105,272 (0%) | 0% | 86.4 | 51,914 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 85.84 per share. | 06 Jul 2026 | 519 | 105,873 (0%) | 0% | 85.8 | 44,551 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 83.10 per share. | 06 Jul 2026 | 387 | 107,698 (0%) | 0% | 83.1 | 32,160 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 83.10 per share. | 06 Jul 2026 | 313 | 107,225 (0%) | 0% | 83.1 | 26,010 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 17 Jun 2026 | 8,510 | 113,722 (0%) | 0% | 46.5 | 396,055 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2026 | 8,510 | 32,950 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.50 per share. | 17 Jun 2026 | 6,600 | 107,122 (0%) | 0% | 78.5 | 518,100 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 17 Jun 2026 | 2,012 | 107,284 (0%) | 0% | 46.5 | 93,638 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2026 | 2,012 | 30,938 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.24 per share. | 17 Jun 2026 | 1,850 | 105,272 (0%) | 0% | 79.2 | 146,594 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.50 per share. | 17 Jun 2026 | 1,703 | 105,581 (0%) | 0% | 78.5 | 133,686 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.25 per share. | 17 Jun 2026 | 309 | 105,272 (0%) | 0% | 79.2 | 24,488 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 2,812 | 19,689 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 15 May 2026 | 2,812 | 108,024 (0%) | 0% | 25.7 | 72,240 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 72.08 per share. | 15 May 2026 | 2,356 | 105,668 (0%) | 0% | 72.1 | 169,820 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 72.67 per share. | 15 May 2026 | 456 | 105,212 (0%) | 0% | 72.7 | 33,138 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 08 May 2026 | 2,740 | 107,952 (0%) | 0% | 46.5 | 127,520 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2026 | 2,740 | 42,260 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.31 per share. | 08 May 2026 | 1,900 | 105,212 (0%) | 0% | 79.3 | 150,689 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.23 per share. | 08 May 2026 | 840 | 107,112 (0%) | 0% | 78.2 | 65,713 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2026 | 800 | 41,460 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.54 per share. | 08 May 2026 | 800 | 106,012 (0%) | 0% | 46.5 | 37,232 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.28 per share. | 08 May 2026 | 600 | 105,212 (0%) | 0% | 79.3 | 47,568 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.00 per share. | 08 May 2026 | 200 | 105,812 (0%) | 0% | 78 | 15,600 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 06 Apr 2026 | 2,265 | 107,477 (0%) | 0% | 39.4 | 89,286 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 2,265 | 6,798 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 69.75 per share. | 06 Apr 2026 | 1,443 | 105,212 (0%) | 0% | 69.7 | 100,649 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 68.91 per share. | 06 Apr 2026 | 822 | 106,655 (0%) | 0% | 68.9 | 56,644 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.56 per share. | 08 Jan 2026 | 2,482 | 115,177 (0%) | 0% | 76.6 | 190,022 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.46 per share. | 08 Jan 2026 | 1,521 | 112,105 (0%) | 0% | 77.5 | 117,817 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.45 per share. | 08 Jan 2026 | 1,286 | 113,626 (0%) | 0% | 76.5 | 98,315 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.71 per share. | 08 Jan 2026 | 686 | 111,419 (0%) | 0% | 78.7 | 53,995 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.07 per share. | 08 Jan 2026 | 265 | 114,912 (0%) | 0% | 77.1 | 20,424 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.52 per share. | 08 Jan 2026 | 107 | 111,312 (0%) | 0% | 79.5 | 8,509 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 2,625 | 751 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 06 Jan 2026 | 2,625 | 120,284 (0%) | 0% | 38.1 | 100,013 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.95 per share. | 06 Jan 2026 | 1,739 | 119,162 (0%) | 0% | 76.9 | 133,816 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.11 per share. | 06 Jan 2026 | 1,638 | 118,646 (0%) | 0% | 77.1 | 126,306 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.48 per share. | 06 Jan 2026 | 1,503 | 117,659 (0%) | 0% | 77.5 | 116,452 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.91 per share. | 06 Jan 2026 | 949 | 117,697 (0%) | 0% | 77.9 | 73,937 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 751 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 06 Jan 2026 | 751 | 118,410 (0%) | 0% | 38.1 | 28,613 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.10 per share. | 06 Jan 2026 | 471 | 117,939 (0%) | 0% | 77.1 | 36,314 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.92 per share. | 06 Jan 2026 | 269 | 117,670 (0%) | 0% | 77.9 | 20,960 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.61 per share. | 06 Jan 2026 | 38 | 117,659 (0%) | 0% | 78.6 | 2,987 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.00 per share. | 06 Jan 2026 | 11 | 117,659 (0%) | 0% | 79 | 869 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 17,000 | 120,901 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 02 Jan 2026 | 2,266 | 123,167 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 2,266 | 9,063 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 74.92 per share. | 02 Jan 2026 | 1,123 | 122,044 (0%) | 0% | 74.9 | 84,135 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.10 per share. | 02 Jan 2026 | 1,035 | 121,009 (0%) | 0% | 76.1 | 78,764 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.79 per share. | 02 Jan 2026 | 108 | 120,901 (0%) | 0% | 76.8 | 8,293 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 17 Nov 2025 | 2,812 | 106,713 (0%) | 0% | 25.7 | 72,240 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 2,812 | 25,314 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 75.64 per share. | 17 Nov 2025 | 1,843 | 104,870 (0%) | 0% | 75.6 | 139,405 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.53 per share. | 17 Nov 2025 | 777 | 104,093 (0%) | 0% | 76.5 | 59,464 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.18 per share. | 17 Nov 2025 | 192 | 103,901 (0%) | 0% | 77.2 | 14,819 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 07 Oct 2025 | 3,375 | 107,276 (0%) | 0% | 38.1 | 128,588 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2025 | 3,375 | 3,376 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 62.89 per share. | 07 Oct 2025 | 1,757 | 105,519 (0%) | 0% | 62.9 | 110,498 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 63.80 per share. | 07 Oct 2025 | 1,306 | 104,213 (0%) | 0% | 63.8 | 83,323 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.97 per share. | 07 Oct 2025 | 312 | 103,901 (0%) | 0% | 65.0 | 20,271 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 18,124 | 122,025 (0%) | 0% | 39.4 | 714,448 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 18,124 | 18,126 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 66.44 per share. | 03 Oct 2025 | 7,400 | 105,401 (0%) | 0% | 66.4 | 491,656 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.47 per share. | 03 Oct 2025 | 6,124 | 112,801 (0%) | 0% | 65.5 | 400,938 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.43 per share. | 03 Oct 2025 | 3,100 | 118,925 (0%) | 0% | 64.4 | 199,733 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 2,266 | 11,329 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 2,266 | 15,860 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.07 per share. | 03 Oct 2025 | 2,266 | 103,901 (0%) | 0% | 65.1 | 147,449 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 2,266 | 106,167 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 2,266 | 106,167 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 2,265 | 13,595 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 2,265 | 106,166 (0%) | 0% | 39.4 | 89,286 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 67.15 per share. | 03 Oct 2025 | 1,500 | 103,901 (0%) | 0% | 67.2 | 100,725 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 66.63 per share. | 03 Oct 2025 | 906 | 103,901 (0%) | 0% | 66.6 | 60,367 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 66.67 per share. | 03 Oct 2025 | 877 | 103,901 (0%) | 0% | 66.7 | 58,470 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.72 per share. | 03 Oct 2025 | 838 | 104,778 (0%) | 0% | 65.7 | 55,073 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.73 per share. | 03 Oct 2025 | 824 | 104,807 (0%) | 0% | 65.7 | 54,162 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.44 per share. | 03 Oct 2025 | 550 | 105,616 (0%) | 0% | 64.4 | 35,442 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.43 per share. | 03 Oct 2025 | 536 | 105,631 (0%) | 0% | 64.4 | 34,534 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 22,661 | 8,675 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 22,661 | 126,562 (0%) | 0% | 38.1 | 863,384 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.33 per share. | 11 Sep 2025 | 22,117 | 104,445 (0%) | 0% | 61.3 | 1,356,436 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 17,838 | 121,739 (0%) | 0% | 38.1 | 679,628 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 17,838 | 36,162 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 11 Sep 2025 | 17,838 | 103,901 (0%) | 0% | 61 | 1,088,118 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 2,470 | 31,336 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 11 Sep 2025 | 2,470 | 103,901 (0%) | 0% | 61 | 150,670 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 2,470 | 106,371 (0%) | 0% | 38.1 | 94,107 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 2,356 | 33,806 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 11 Sep 2025 | 2,356 | 103,901 (0%) | 0% | 61 | 143,716 | Common Stock |